We are analyzing https://link.springer.com/article/10.1186/1471-2407-14-74.

Title:
TRAIL-induced programmed necrosis as a novel approach to eliminate tumor cells | BMC Cancer
Description:
Background The cytokine TRAIL represents one of the most promising candidates for the apoptotic elimination of tumor cells, either alone or in combination therapies. However, its efficacy is often limited by intrinsic or acquired resistance of tumor cells to apoptosis. Programmed necrosis is an alternative, molecularly distinct mode of programmed cell death that is elicited by TRAIL under conditions when the classical apoptosis machinery fails or is actively inhibited. The potential of TRAIL-induced programmed necrosis in tumor therapy is, however, almost completely uncharacterized. We therefore investigated its impact on a panel of tumor cell lines of wide-ranging origin. Methods Cell death/viability was measured by flow cytometry/determination of intracellular ATP levels/crystal violet staining. Cell surface expression of TRAIL receptors was detected by flow cytometry, expression of proteins by Western blot. Ceramide levels were quantified by high-performance thin layer chromatography and densitometric analysis, clonogenic survival of cells was determined by crystal violet staining or by soft agarose cloning. Results TRAIL-induced programmed necrosis killed eight out of 14 tumor cell lines. Clonogenic survival was reduced in all sensitive and even one resistant cell lines tested. TRAIL synergized with chemotherapeutics in killing tumor cell lines by programmed necrosis, enhancing their effect in eight out of 10 tested tumor cell lines and in 41 out of 80 chemotherapeutic/TRAIL combinations. Susceptibility/resistance of the investigated tumor cell lines to programmed necrosis seems to primarily depend on expression of the pro-necrotic kinase RIPK3 rather than the related kinase RIPK1 or cell surface expression of TRAIL receptors. Furthermore, interference with production of the lipid ceramide protected all tested tumor cell lines. Conclusions Our study provides evidence that TRAIL-induced programmed necrosis represents a feasible approach for the elimination of tumor cells, and that this treatment may represent a promising new option for the future development of combination therapies. Our data also suggest that RIPK3 expression may serve as a potential predictive marker for the sensitivity of tumor cells to programmed necrosis and extend the previously established role of ceramide as a key mediator of death receptor-induced programmed necrosis (and thus as a potential target for future therapies) also to the tumor cell lines examined here.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Telecommunications
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,932 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

The income method remains a mystery to us.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

cell, necrosis, programmed, cells, tumor, lines, figure, ripk, pubmed, article, trail, google, scholar, apoptosis, death, trailzvadchx, cas, caspase, ceramide, μgml, expression, cancer, shown, treatment, induction, combination, trailinduced, resistance, tnfzvadchx, additional, kns, germany, analyzed, trailr, human, trailzvadchxinduced, control, file, analysis, data, levels, sensitive, study, zvadfmk, chx, tnfzvadchxinduced, staining, addition, ccrfcem, chemotherapeutic,

Topics {✒️}

tnf/zvad/chx-induced necrotic killing tnf/zvad/chx-induced programmed necrosis trail/zvad/chx-induced programmed necrosis tnf/zvad/chx-induced killing trail/zvad/chx-induced killing ceramide mediates trail/zvad/chx trail/zvad/chx synergizes 80 chemotherapeutic/trail/zvad/chx combinations open access article tnf-induced programmed necrosis trail-induced programmed necrosis pre-publication history benzyloxycarbonyl-val-ala-asp tnf/chx-treated positive controls a-smase acts downstream article download pdf caspase-independent cell death renal ischemia/reperfusion injury pro-necrotic kinase ripk3 trail/zvad/chx led bcl-2-family member bmf inducing caspase-independent mechanisms multiple patho-physiological settings apoptosis-resistant cell lines 50 μg/ml penicillin/streptomycin full size image caspase-independent mechanism mediated activates caspase-dependent apoptosis induced cell death apoptosis-resistant cancer cells cell lines ccrf-cem programmed necrosis induced induced programmed necrosis tumor necrosis factor inducing programmed necrosis elicit caspase-dependent apoptosis tnf-induced necrosis central effector caspase 2 μg/ml propidium iodide lipase a-smase trail induces necroptosis anna trauzold zvad/chx-treated cells trail-induced apoptosis programmed cell death mol cancer ther tnf-induced necroptosis pivotal factor downstream anti-trail-r1 platelet-activating factor

Schema {🗺️}

WebPage:
      mainEntity:
         headline:TRAIL-induced programmed necrosis as a novel approach to eliminate tumor cells
         description:The cytokine TRAIL represents one of the most promising candidates for the apoptotic elimination of tumor cells, either alone or in combination therapies. However, its efficacy is often limited by intrinsic or acquired resistance of tumor cells to apoptosis. Programmed necrosis is an alternative, molecularly distinct mode of programmed cell death that is elicited by TRAIL under conditions when the classical apoptosis machinery fails or is actively inhibited. The potential of TRAIL-induced programmed necrosis in tumor therapy is, however, almost completely uncharacterized. We therefore investigated its impact on a panel of tumor cell lines of wide-ranging origin. Cell death/viability was measured by flow cytometry/determination of intracellular ATP levels/crystal violet staining. Cell surface expression of TRAIL receptors was detected by flow cytometry, expression of proteins by Western blot. Ceramide levels were quantified by high-performance thin layer chromatography and densitometric analysis, clonogenic survival of cells was determined by crystal violet staining or by soft agarose cloning. TRAIL-induced programmed necrosis killed eight out of 14 tumor cell lines. Clonogenic survival was reduced in all sensitive and even one resistant cell lines tested. TRAIL synergized with chemotherapeutics in killing tumor cell lines by programmed necrosis, enhancing their effect in eight out of 10 tested tumor cell lines and in 41 out of 80 chemotherapeutic/TRAIL combinations. Susceptibility/resistance of the investigated tumor cell lines to programmed necrosis seems to primarily depend on expression of the pro-necrotic kinase RIPK3 rather than the related kinase RIPK1 or cell surface expression of TRAIL receptors. Furthermore, interference with production of the lipid ceramide protected all tested tumor cell lines. Our study provides evidence that TRAIL-induced programmed necrosis represents a feasible approach for the elimination of tumor cells, and that this treatment may represent a promising new option for the future development of combination therapies. Our data also suggest that RIPK3 expression may serve as a potential predictive marker for the sensitivity of tumor cells to programmed necrosis and extend the previously established role of ceramide as a key mediator of death receptor-induced programmed necrosis (and thus as a potential target for future therapies) also to the tumor cell lines examined here.
         datePublished:2014-02-07T00:00:00Z
         dateModified:2014-02-07T00:00:00Z
         pageStart:1
         pageEnd:14
         license:https://creativecommons.org/licenses/by/2.0
         sameAs:https://doi.org/10.1186/1471-2407-14-74
         keywords:
            Programmed necrosis
            TRAIL
            TNF
            Ceramide
            Chemotherapy
            Cancer Research
            Oncology
            Surgical Oncology
            Health Promotion and Disease Prevention
            Biomedicine
            general
            Medicine/Public Health
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-74/MediaObjects/12885_2013_Article_4304_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-74/MediaObjects/12885_2013_Article_4304_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-74/MediaObjects/12885_2013_Article_4304_Fig3_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-74/MediaObjects/12885_2013_Article_4304_Fig4_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-74/MediaObjects/12885_2013_Article_4304_Fig5_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-74/MediaObjects/12885_2013_Article_4304_Fig6_HTML.jpg
         isPartOf:
            name:BMC Cancer
            issn:
               1471-2407
            volumeNumber:14
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Susann Voigt
               affiliation:
                     name:Institut für Immunologie, Christian-Albrechts-Universität
                     address:
                        name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Stephan Philipp
               affiliation:
                     name:Institut für Immunologie, Christian-Albrechts-Universität
                     address:
                        name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Parvin Davarnia
               affiliation:
                     name:Institut für Immunologie, Christian-Albrechts-Universität
                     address:
                        name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Supandi Winoto-Morbach
               affiliation:
                     name:Institut für Immunologie, Christian-Albrechts-Universität
                     address:
                        name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Christian Röder
               affiliation:
                     name:Christian-Albrechts-Universität
                     address:
                        name:Sektion für Molekulare Onkologie, Institut für Experimentelle Tumorforschung, Christian-Albrechts-Universität, Kiel, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Christoph Arenz
               affiliation:
                     name:Institut für Chemie der Humboldt-Universität
                     address:
                        name:Institut für Chemie der Humboldt-Universität, Berlin, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Anna Trauzold
               affiliation:
                     name:Christian-Albrechts-Universität
                     address:
                        name:Sektion für Molekulare Onkologie, Institut für Experimentelle Tumorforschung, Christian-Albrechts-Universität, Kiel, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Dieter Kabelitz
               affiliation:
                     name:Institut für Immunologie, Christian-Albrechts-Universität
                     address:
                        name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Stefan Schütze
               affiliation:
                     name:Institut für Immunologie, Christian-Albrechts-Universität
                     address:
                        name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Holger Kalthoff
               affiliation:
                     name:Christian-Albrechts-Universität
                     address:
                        name:Sektion für Molekulare Onkologie, Institut für Experimentelle Tumorforschung, Christian-Albrechts-Universität, Kiel, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Dieter Adam
               affiliation:
                     name:Institut für Immunologie, Christian-Albrechts-Universität
                     address:
                        name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:TRAIL-induced programmed necrosis as a novel approach to eliminate tumor cells
      description:The cytokine TRAIL represents one of the most promising candidates for the apoptotic elimination of tumor cells, either alone or in combination therapies. However, its efficacy is often limited by intrinsic or acquired resistance of tumor cells to apoptosis. Programmed necrosis is an alternative, molecularly distinct mode of programmed cell death that is elicited by TRAIL under conditions when the classical apoptosis machinery fails or is actively inhibited. The potential of TRAIL-induced programmed necrosis in tumor therapy is, however, almost completely uncharacterized. We therefore investigated its impact on a panel of tumor cell lines of wide-ranging origin. Cell death/viability was measured by flow cytometry/determination of intracellular ATP levels/crystal violet staining. Cell surface expression of TRAIL receptors was detected by flow cytometry, expression of proteins by Western blot. Ceramide levels were quantified by high-performance thin layer chromatography and densitometric analysis, clonogenic survival of cells was determined by crystal violet staining or by soft agarose cloning. TRAIL-induced programmed necrosis killed eight out of 14 tumor cell lines. Clonogenic survival was reduced in all sensitive and even one resistant cell lines tested. TRAIL synergized with chemotherapeutics in killing tumor cell lines by programmed necrosis, enhancing their effect in eight out of 10 tested tumor cell lines and in 41 out of 80 chemotherapeutic/TRAIL combinations. Susceptibility/resistance of the investigated tumor cell lines to programmed necrosis seems to primarily depend on expression of the pro-necrotic kinase RIPK3 rather than the related kinase RIPK1 or cell surface expression of TRAIL receptors. Furthermore, interference with production of the lipid ceramide protected all tested tumor cell lines. Our study provides evidence that TRAIL-induced programmed necrosis represents a feasible approach for the elimination of tumor cells, and that this treatment may represent a promising new option for the future development of combination therapies. Our data also suggest that RIPK3 expression may serve as a potential predictive marker for the sensitivity of tumor cells to programmed necrosis and extend the previously established role of ceramide as a key mediator of death receptor-induced programmed necrosis (and thus as a potential target for future therapies) also to the tumor cell lines examined here.
      datePublished:2014-02-07T00:00:00Z
      dateModified:2014-02-07T00:00:00Z
      pageStart:1
      pageEnd:14
      license:https://creativecommons.org/licenses/by/2.0
      sameAs:https://doi.org/10.1186/1471-2407-14-74
      keywords:
         Programmed necrosis
         TRAIL
         TNF
         Ceramide
         Chemotherapy
         Cancer Research
         Oncology
         Surgical Oncology
         Health Promotion and Disease Prevention
         Biomedicine
         general
         Medicine/Public Health
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-74/MediaObjects/12885_2013_Article_4304_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-74/MediaObjects/12885_2013_Article_4304_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-74/MediaObjects/12885_2013_Article_4304_Fig3_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-74/MediaObjects/12885_2013_Article_4304_Fig4_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-74/MediaObjects/12885_2013_Article_4304_Fig5_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-74/MediaObjects/12885_2013_Article_4304_Fig6_HTML.jpg
      isPartOf:
         name:BMC Cancer
         issn:
            1471-2407
         volumeNumber:14
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Susann Voigt
            affiliation:
                  name:Institut für Immunologie, Christian-Albrechts-Universität
                  address:
                     name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Stephan Philipp
            affiliation:
                  name:Institut für Immunologie, Christian-Albrechts-Universität
                  address:
                     name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Parvin Davarnia
            affiliation:
                  name:Institut für Immunologie, Christian-Albrechts-Universität
                  address:
                     name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Supandi Winoto-Morbach
            affiliation:
                  name:Institut für Immunologie, Christian-Albrechts-Universität
                  address:
                     name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Christian Röder
            affiliation:
                  name:Christian-Albrechts-Universität
                  address:
                     name:Sektion für Molekulare Onkologie, Institut für Experimentelle Tumorforschung, Christian-Albrechts-Universität, Kiel, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Christoph Arenz
            affiliation:
                  name:Institut für Chemie der Humboldt-Universität
                  address:
                     name:Institut für Chemie der Humboldt-Universität, Berlin, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Anna Trauzold
            affiliation:
                  name:Christian-Albrechts-Universität
                  address:
                     name:Sektion für Molekulare Onkologie, Institut für Experimentelle Tumorforschung, Christian-Albrechts-Universität, Kiel, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Dieter Kabelitz
            affiliation:
                  name:Institut für Immunologie, Christian-Albrechts-Universität
                  address:
                     name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Stefan Schütze
            affiliation:
                  name:Institut für Immunologie, Christian-Albrechts-Universität
                  address:
                     name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Holger Kalthoff
            affiliation:
                  name:Christian-Albrechts-Universität
                  address:
                     name:Sektion für Molekulare Onkologie, Institut für Experimentelle Tumorforschung, Christian-Albrechts-Universität, Kiel, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Dieter Adam
            affiliation:
                  name:Institut für Immunologie, Christian-Albrechts-Universität
                  address:
                     name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:BMC Cancer
      issn:
         1471-2407
      volumeNumber:14
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Institut für Immunologie, Christian-Albrechts-Universität
      address:
         name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
         type:PostalAddress
      name:Institut für Immunologie, Christian-Albrechts-Universität
      address:
         name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
         type:PostalAddress
      name:Institut für Immunologie, Christian-Albrechts-Universität
      address:
         name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
         type:PostalAddress
      name:Institut für Immunologie, Christian-Albrechts-Universität
      address:
         name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
         type:PostalAddress
      name:Christian-Albrechts-Universität
      address:
         name:Sektion für Molekulare Onkologie, Institut für Experimentelle Tumorforschung, Christian-Albrechts-Universität, Kiel, Germany
         type:PostalAddress
      name:Institut für Chemie der Humboldt-Universität
      address:
         name:Institut für Chemie der Humboldt-Universität, Berlin, Germany
         type:PostalAddress
      name:Christian-Albrechts-Universität
      address:
         name:Sektion für Molekulare Onkologie, Institut für Experimentelle Tumorforschung, Christian-Albrechts-Universität, Kiel, Germany
         type:PostalAddress
      name:Institut für Immunologie, Christian-Albrechts-Universität
      address:
         name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
         type:PostalAddress
      name:Institut für Immunologie, Christian-Albrechts-Universität
      address:
         name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
         type:PostalAddress
      name:Christian-Albrechts-Universität
      address:
         name:Sektion für Molekulare Onkologie, Institut für Experimentelle Tumorforschung, Christian-Albrechts-Universität, Kiel, Germany
         type:PostalAddress
      name:Institut für Immunologie, Christian-Albrechts-Universität
      address:
         name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Susann Voigt
      affiliation:
            name:Institut für Immunologie, Christian-Albrechts-Universität
            address:
               name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
               type:PostalAddress
            type:Organization
      name:Stephan Philipp
      affiliation:
            name:Institut für Immunologie, Christian-Albrechts-Universität
            address:
               name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
               type:PostalAddress
            type:Organization
      name:Parvin Davarnia
      affiliation:
            name:Institut für Immunologie, Christian-Albrechts-Universität
            address:
               name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
               type:PostalAddress
            type:Organization
      name:Supandi Winoto-Morbach
      affiliation:
            name:Institut für Immunologie, Christian-Albrechts-Universität
            address:
               name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
               type:PostalAddress
            type:Organization
      name:Christian Röder
      affiliation:
            name:Christian-Albrechts-Universität
            address:
               name:Sektion für Molekulare Onkologie, Institut für Experimentelle Tumorforschung, Christian-Albrechts-Universität, Kiel, Germany
               type:PostalAddress
            type:Organization
      name:Christoph Arenz
      affiliation:
            name:Institut für Chemie der Humboldt-Universität
            address:
               name:Institut für Chemie der Humboldt-Universität, Berlin, Germany
               type:PostalAddress
            type:Organization
      name:Anna Trauzold
      affiliation:
            name:Christian-Albrechts-Universität
            address:
               name:Sektion für Molekulare Onkologie, Institut für Experimentelle Tumorforschung, Christian-Albrechts-Universität, Kiel, Germany
               type:PostalAddress
            type:Organization
      name:Dieter Kabelitz
      affiliation:
            name:Institut für Immunologie, Christian-Albrechts-Universität
            address:
               name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
               type:PostalAddress
            type:Organization
      name:Stefan Schütze
      affiliation:
            name:Institut für Immunologie, Christian-Albrechts-Universität
            address:
               name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
               type:PostalAddress
            type:Organization
      name:Holger Kalthoff
      affiliation:
            name:Christian-Albrechts-Universität
            address:
               name:Sektion für Molekulare Onkologie, Institut für Experimentelle Tumorforschung, Christian-Albrechts-Universität, Kiel, Germany
               type:PostalAddress
            type:Organization
      name:Dieter Adam
      affiliation:
            name:Institut für Immunologie, Christian-Albrechts-Universität
            address:
               name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
      name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
      name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
      name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
      name:Sektion für Molekulare Onkologie, Institut für Experimentelle Tumorforschung, Christian-Albrechts-Universität, Kiel, Germany
      name:Institut für Chemie der Humboldt-Universität, Berlin, Germany
      name:Sektion für Molekulare Onkologie, Institut für Experimentelle Tumorforschung, Christian-Albrechts-Universität, Kiel, Germany
      name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
      name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany
      name:Sektion für Molekulare Onkologie, Institut für Experimentelle Tumorforschung, Christian-Albrechts-Universität, Kiel, Germany
      name:Institut für Immunologie, Christian-Albrechts-Universität, Kiel, Germany

External Links {🔗}(179)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.85s.

LINK . SPRINGER . COM {}